Event Schedule Three

2022 New Zealand Melanoma Summit > Event Schedule Three
Day 1 Agenda

First Day

8:00 am
---
9:20 am

Opening session

Opening address
Guest speaker

2021 Melanoma Summit overview
Dr Chris Boberg, Chair 2021 New Zealand Melanoma Summit Planning Committee and Co-Chair, MelNet

Patient challenge
Terence Walsh, Patient representative

Melanoma in the New Zealand cancer landscape
Professor Diana Sarfati, National Director of Cancer Control and Chief Executive, Te Aho o Te Kahu - Cancer Control Agency

Quality Statements for to Guide Melanoma Diagnosis and Treatment in New Zealand
Dr Richard Martin, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board and Chair Melanoma Quality Statements Working Group

9:20 am
---
10:30 am

Session 1: Epidemiology and primary prevention

Epidemiological trends in melanoma
Professor David Whiteman, Deputy Director, Head of Cancer Control Laboratory and Coordinator, Melanoma and Skin Cancer Research Centre, QIMR Berghofer Medical Research Institute, Queensland, Australia

What is happening about sunscreens in New Zealand?
Jon Duffy, Chief Executive, Consumer New Zealand
Dr Louise Reiche, Dermatologist, Kauri Healthcare Palmerston North and Immediate Past President, New Zealand Dermatological Society Incorporated 

My story
Todd Muller, Patient representative

Questions and discussion
11.00 am
---
12.00 noon

Session 2: Early detection

Early detection saves lives: Our story
Chris and Judy Bailey, Patient representatives

The evolution of early detection, dermatoscopy and artificial intelligence
Professor Cliff Rosendahl, Course Coordinator of the Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia
Adjunct Associate Professor Amanda Oakley, Dermatologist, Waikato District Health Board

Questions and discussion
12.00 noon
---
12:30 pm

Session 3: Controversy of borderline lesions

Clinico-histological collaboration
Professor Cliff Rosendahl, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia
Dr Ben Tallon, Dermatologist, SKIN Dermatology Institute and Dermatopathologist, Pathlab, Tauranga
Dr Richard Massey, Pathologist and Director, Pathology Associates, Tauranga
Dr Michael Hitchcock, Pathologist and Clinical Lead, Anatomic Pathology Services, Auckland District Health Board

Questions and discussion

1:30 pm
---
2:45 pm

Session 4: Concurrent breakout session 1

Breakout 4A - New Zealand primary prevention and early detection initiatives
This session will highlight and discuss primary prevention and early detection initiatives underway in the sector. It will also discuss the New Zealand Skin Cancer Primary Prevention and Early Detection Strategy and its alignment with the Te Aho o te Kahu – Cancer Control Agency ‘Prevention Strategies’ report.

Breakout 4B - Dermatoscopy in action
In this session Professor Cliff Rosendahl will teach the basics of the ‘chaos and clues’ approach to dermatoscopy in diagnosing melanoma and will demonstrate its practical application to specific cases.

Breakout 4C - MelNet melanoma multi-disciplinary meeting: challenging cases
In this session, a multi-disciplinary panel will discuss the clinical management of a range of challenging or unusual cases of melanoma.

Breakout 4D - Upcoming research and innovations
Presenters whose submitted abstracts have been selected will provide snapshots of upcoming research and clinical innovations
3:15 pm
---
4:15 pm

Session 5: Paving the way for high quality, collaborative melanoma care

Waitemata District Health Board: a collaborative skin cancer care model
Dr Daniel Wen, House Officer, Waitemata District Health Board

Nurse led dermatoscopy clinics: the way of the future?
Katy Doherty, Managing Director, Espy Skin, Auckland
Trish Baker, Managing Director, Healthbox NZ Ltd, Auckland

Serious Illness Conversation Guide
Jane Goodwin, Advance Care Planning Facilitator, Health Quality and Safety Commission and Registered Nurse, Canterbury District Health Board

4.15 pm
---
5.00 pm

Session 6: Concurrent breakout session 2

Breakout 6A - Pathology synoptic reporting and histology updatee
This session will update on progress towards consistent synoptic reporting for skin cancer.

Breakout 6B - New Zealand melanoma research and therapy special interest group
Intended for those involved or interested in being part of the Melanoma Research and Therapy Special Interest or those with an interest in research or therapy.

Breakout 6C - Serious Illness Conversation Guide
Using the Serious Illness Conversation Guide, this session will build on the plenary session to help develop skills and confidence in having difficult conversations with patients and their whanau.

Breakout 6D - GPs with a special interest in skin cancer
Intended for those who are part of or interested in joining New Zealand Skin Cancer Doctors. The session will provide an overview of New Zealand Skin Cancer Doctors and the work they do. It will also include a discussion of interesting dermatoscopic and surgical cases. Attendees are encouraged to bring along cases to discuss.
5.00 pm
---
5.15 pm

Session 7: Day one wrap up

Highlights and recommendations from breakout sessions and day one summary
5:15 pm
---
5:30 pm
5:30 pm
---
7:30 pm
Day 2 Agenda

Second Day

8:00 am
---
9:30 am

Session 8: State of the art melanoma management

My story Dr Jeff Dalley, Patient representative

In situ melanoma - current best practice in New Zealand Dr Andrew MacGill, Director, SkinCheck Northcote, Auckland and fully accredited member of New Zealand Skin Cancer Doctors Society 

Mohs surgery for melanoma Dr Paul Salmon, Dermatologist, Skin Centre Tauranga and Auckland Dermatology

The current role of sentinel node biopsy in managing primary melanoma Dr Mark Faries, Professor of Surgery and Co-Director Cutaneous Oncology Program, The Angeles Clinic and Research Institute and Cedars-Sinai Medical Center, Los Angeles, USA

Questions and discussion
10:00 am
---
12:00 noon

Session 9: Advanced melanoma management

My story
Tim Stevens, Patient representative

The future and evolution of adjuvant and neoadjuvant therapy
Dr Inês Pires da Silva, Medical Oncologist and Researcher Scientist at Melanoma Institute Australia, Westmead and Blacktown Hospitals, and University of Sydney

The New Zealand situation
Dr Jody Jordan, Medical Oncologist, Hawke’s Bay District Health Board and Canopy Cancer Care, Hastings

Nurses care perspective on managing advanced melanoma
Jo Tuaine, Oncology Clinical Nurse Specialist, Southern Blood and Cancer Service, Southern District Health Board

Questions and discussion
1:00 pm
---
1:40 pm

Session 10: Melanoma and genetics

Current status of molecular profiling of melanoma
Professor Grant McArthur, Head Molecular Oncology Laboratory, Peter MacCallum Cancer Centre and Executive Director, Victoria Comprehensive Cancer Centre, Melbourne, Australia

Questions and discussion
1:40 pm
---
2:30 pm

Session 11: The economics of the skin cancer epidemic

Escalating the economic burden of skin cancer to Government
Associate Professor Louisa Gordon, Group Leader Health Economics, QIMR Berghofer Medical Research Institute

The private sector
Dr Stephen Child, Chief Medical Officer, Southern Cross

Questions and discussion  

2:30 pm
---
3:15 pm

Session 12: Concurrent breakout session 3

Breakout 12A - Priorities for action – primary prevention
This session will workshop priorities for action for New Zealand that support primary prevention.

Breakout 12B - Priorities for action – early detection
This session will workshop priorities for action for New Zealand that support early detection.

Breakout 12C - Priorities for action – clinical management of advanced disease and research
This session will workshop priorities for action for New Zealand relating to the clinical management of advanced disease and research.
3:45 pm
---
5:00 pm

Session 13: Looking to the future of melanoma

Setting the priorities for action - recommendations from concurrent breakout session 3

Panel: The future of melanoma prevention, diagnosis, treatment, care and research

Patient perspective - the final say

Wrap up, recommendations and closing remarks
Day 3 Agenda

Third Day